Abstract
Carcinoembryonic antigen (CEA) family members play important roles in malignancies and are introduced as biomarkers in different types of cancers. Among them CEACAM19 (CEAL1) gene, a new member of the CEA family, remains to be fully elucidated. The aim of this study was investigating the mRNA expression level of CEACAM19 in tumor samples of breast cancer patients compared to breast tissue of normal individuals. We evaluated the expression level of this gene in 75 breast tumors by using real-time quantitative PCR. Also, we studied the correlation between CEACAM19 expression and clinicopathological features and hormone receptors status, including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 of patients. Out of the enrolled patients, six of them (7.9%) showed low expression, ten (13.2%) showed normal expression and 59 (77.6%) showed high expression of CEACAM19. There was a significant correlation between high expression of CEACAM19 gene in tumor samples compared to normal tissues (P = 0.039). No significant correlation was seen between clinicopathological factors and disease-free survival with mRNA levels of CEACAM19 in tumor samples, while the difference between the expression of CEACAM19 in ER/PR-positive and ER/PR-negative breast cancer patients was statistically significant (P = 0.046). In conclusion, CEACAM19 showed high expression in tumor samples compared to normal mammary tissue. In addition, CEACAM19 may represent as a novel therapeutic target in certain subgroups of breast cancer patients such as ER/PR-negative. Critical roles of CEA proteins in tumor progression may nominate them as robust potential targets for therapeutic intervention in near future.
Similar content being viewed by others
References
Harding C, Pompei F, Burmistrov D, Welch HG, Abebe R, Wilson R. Breast cancer screening, incidence, and mortality across US counties. JAMA Intern Med. 2015;175:1483–9.
Sharifian A, Pourhoseingholi MA, Emadedin M, et al. Burden of breast cancer in Iranian women is increasing. Asian Pac J Cancer Prev. 2015;16:5049–52.
Si W, Li Y, Han Y, et al. Epidemiological and clinicopathological trends of breast cancer in Chinese patients during 1993 to 2013: a retrospective study. Medicine. 2015;94:e820.
Györffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.
Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22:6524–36.
Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol. 2006;18:565–71.
Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metast Rev. 2013;32:643–71.
Wakabayashi-Nakao K, Hatakeyama K, Ohshima K, Yamaguchi K, Mochizuki T. Carcinoembryonic antigen-related cell adhesion molecule 4 (CEACAM4) is specifically expressed in medullary thyroid carcinoma cells. Biomed Res. 2014;35:237–42.
Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 2007;7:2.
Zhou J, Zhang L, Gu Y, et al. Dynamic expression of CEACAM7 in precursor lesions of gastric carcinoma and its prognostic value in combination with CEA. World J Surg Oncol. 2011;9:172.
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene. 2004;23:465–73.
Singer BB, Scheffrahn I, Kammerer R, et al. Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS ONE. 2010;5:e8747.
Chan C, Stanners C. Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6. Curr Oncol. 2007;14:70.
Horst A, Wagener C. CEA-related CAMs. Handb Exp Pharmacol. 2004;165:283–341.
Tiernan J, Perry S, Verghese E, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013;108:662–7.
Kim KS, Kim J-T, Lee S-J, et al. Overexpression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in colorectal cancer. Clin Chim Acta. 2013;415:12–9.
Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20:2530–6.
Laack E, Nikbakht H, Peters A, et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol. 2002;20:4279–84.
Scorilas A, Chiang PM, Katsaros D, Yousef GM, Diamandis EP. Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. Gene. 2003;310:79–89.
Majidzadeh-A K, Kaviani A, Esmaeili R, et al. Iranian breast cancer bio-bank: the activity and challenging issues. Cell Tissue Bank. 2013;14:11–20.
Majidzadeh-A K, Esmaeili R, Abdoli N. TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen activator in breast cancer. BMC Res Notes. 2011;4:215.
Pazhoomand R, Keyhani E, Banan M, et al. Detection of HER2 status in breast cancer: comparison of current methods with MLPA and real-time RT-PCR. Asian Pac J Cancer Prev. 2013;14:7621–8.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA-Cancer J Clin. 2015;65:5–29.
Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the USA, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30–54.
Babu GR, Samari G, Cohen SP, et al. Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev. 2011;12:1647–55.
Khatib N, Pe’er J, Ortenberg R, et al. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers. Invest Ophthalmol Vis Sci. 2011;13:9368–72.
Dango S, Sienel W, Schreiber M, et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. Lung Cancer. 2008;60:426–33.
Zhou C-J, Liu B, Zhu K-X, et al. The different expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and possible roles in gastric carcinomas. Pathol Res Pract. 2009;205:483–9.
Thöm I, Schult-Kronefeld O, Burkholder I, et al. Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res. 2009;29:249–54.
Gebauer F, Wicklein D, Horst J, et al. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. PLoS ONE. 2014;9:e113023.
Serra S, Asa SL, Bamberger A-M, Wagener C, Chetty R. CEACAM1 expression in pancreatic endocrine tumors. Appl Immunohistochem Mol Morphol. 2009;17:286–93.
Cruz PV, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K. Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma. Cancer. 2005;104:354–60.
Busch C, Hanssen TA, Wagener C, Öbrink B. Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum Pathol. 2002;33:290–8.
Strickland LA, Ross J, Williams S, et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol. 2009;218:380–90.
Hasselbalch HC, Skov V, Larsen TS, et al. High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis. Leuk Res. 2011;35:1330–4.
Messick CA, Sanchez J, DeJulius KL, Hammel J, Ishwaran H, Kalady MF. CEACAM-7: a predictive marker for rectal cancer recurrence. Surgery. 2010;147:713–9.
Michaelidou K, Tzovaras A, Missitzis I, Ardavanis A, Scorilas A. The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression. Int J Oncol. 2013;42:1770–7.
Hashemzadeh S, Arabzadeh AA, Estiar MA, et al. Clinical utility of measuring expression levels of Stanniocalcin 2 in patients with colorectal cancer. Med Oncol. 2014;31:237.
Saadatmand S, de Kruijf E, Sajet A, et al. Expression of cell adhesion molecules and prognosis in breast cancer. Brit J Surg. 2013;100:252–60.
Poola I, Shokrani B, Bhatnagar R, DeWitty RL, Yue Q, Bonney G. Expression of carcinoembryonic antigen cell adhesion molecule 6 oncoprotein in atypical ductal hyperplastic tissues is associated with the development of invasive breast cancer. Clin Cancer Res. 2006;12:4773–83.
Hauck W, Nedellec P, Turbide C, Stanners CP, Barnett TR, Beauchemin N. Transcriptional control of the human biliary glycoprotein gene, a CEA gene family member down-regulated in colorectal carcinomas. Eur J Biochem. 1994;223:529–41.
Kobayashi M, Miki Y, Ebina M, et al. Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. Brit J Cancer. 2012;107:1745–53.
Sienel W, Dango S, Woelfle U, et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res. 2003;9:2260–6.
Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells. Cancer Res. 2009;69:1722–7.
Motamedi S, Majidzadeh K, Mazaheri M, Anbiaie R, Mortazavizadeh SM, Esmaeili R. Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients. Asian Pac J Cancer Prev. 2012;13:6101–4.
Majidzadeh-A K, Gharechahi J. Plasma proteomics analysis of tamoxifen resistance in breast cancer. Med Oncol. 2013;30:753.
Scott D, Parkes A, Ponchel F, Cummings M, Poola I, Speirs V. Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol. 2007;31:557–65.
Maraqa L, Cummings M, Peter MB, et al. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res. 2008;14:405–11.
Lewis-Wambi J, Kim H, Cunliffe H, Jordan C. Overexpression of CEACAM6 promotes invasion and migration of aromatase inhibitor-resistant breast cancer cells. Cancer Res. 2007;67:5710.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There is no conflict of interest.
Rights and permissions
About this article
Cite this article
Estiar, M.A., Esmaeili, R., Zare, AA. et al. High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer. Clin Exp Med 17, 547–553 (2017). https://doi.org/10.1007/s10238-016-0442-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-016-0442-1